{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:52:17Z","timestamp":1786996337392,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T00:00:00Z","timestamp":1675123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Spanish Journal of Psychiatry and Mental Health"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.rpsm.2023.01.003","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T21:49:11Z","timestamp":1675115351000},"page":"231-238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Pharmacological treatment for challenging behavior in adults with intellectual disability: Systematic review and meta-analysis"],"prefix":"10.1016","volume":"17","author":[{"given":"Rodrigo","family":"Campos-Jara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Mart\u00ednez-Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Campos-Jara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dar\u00edo","family":"Mart\u00ednez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falonn","family":"Contreras-Osorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpsm.2023.01.003_bib0185","series-title":"Intellectual disability","author":"Lee","year":"2022"},{"key":"10.1016\/j.rpsm.2023.01.003_bib0190","series-title":"Current state of knowledge on the prevalence of neurodevelopmental disorders in childhood according to the DSM-5: a systematic review in accordance with the PRISMA criteria. Vol. 16. Child and adolescent psychiatry and mental health. England","first-page":"27","author":"Franc\u00e9s","year":"2022"},{"key":"10.1016\/j.rpsm.2023.01.003_bib0195","unstructured":"Organization WH. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva PP \u2013 Geneva: World Health Organization."},{"key":"10.1016\/j.rpsm.2023.01.003_bib0200","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/bjc.12118","article-title":"Challenging behaviours in adults with an intellectual disability: a total population study and exploration of risk indices","volume":"56","author":"Bowring","year":"2017","journal-title":"Br J Clin Psychol"},{"issue":"Pt 8","key":"10.1016\/j.rpsm.2023.01.003_bib0205","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1365-2788.2006.00948.x","article-title":"Challenging behaviours: prevalence and topographies","volume":"51","author":"Lowe","year":"2007","journal-title":"J Intellect Disabil Res"},{"key":"10.1016\/j.rpsm.2023.01.003_bib0210","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.ridd.2013.01.010","article-title":"Prevalence and risk markers of behavior problems among adults with intellectual disabilities: a total population study in \u00d6rebro County, Sweden","volume":"34","author":"Lundqvist","year":"2013","journal-title":"Res Dev Disabil"},{"key":"10.1016\/j.rpsm.2023.01.003_bib0215","series-title":"Challenging Behaviour and Learning Disabilities: Prevention and Interventions for People with Learning Disabilities Whose Behaviour Challenges. National Institute for Health and Care Excellence (NICE). London","year":"2015"},{"key":"10.1016\/j.rpsm.2023.01.003_bib0220","first-page":"786","article-title":"Voorschrijven van psychofarmaca bij mensen met een verstandelijke beperking: Handvatten voor de praktijk","volume":"61","author":"De Kuijper","year":"2019","journal-title":"Tijdschr Psychiatr"},{"key":"10.1016\/j.rpsm.2023.01.003_bib0225","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/jir.12685","article-title":"Psychotropic medication use in adults with intellectual disability in Queensland Australia, from 1999 to 2015: a cohort study","volume":"64","author":"Song","year":"2020","journal-title":"J Intellect Disabil Res"},{"key":"10.1016\/j.rpsm.2023.01.003_bib0230","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ridd.2004.03.004","article-title":"Psychotropic medication in adults with mental retardation: prevalence, and prescription practices","volume":"25","author":"Holden","year":"2004","journal-title":"Res Dev Disabil"},{"key":"10.1016\/j.rpsm.2023.01.003_bib0235","doi-asserted-by":"crossref","first-page":"h4326","DOI":"10.1136\/bmj.h4326","article-title":"Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study","volume":"351","author":"Sheehan","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.rpsm.2023.01.003_bib0240","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/0706743717727240","article-title":"Antipsychotic use with and without comorbid psychiatric diagnosis among adults with intellectual and developmental disabilities","volume":"63","author":"Lunsky","year":"2018","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.rpsm.2023.01.003_bib0245","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/jir.12471","article-title":"Problem behaviours and psychotropic medication use in intellectual disability: a multinational cross-sectional survey","volume":"62","author":"Perry","year":"2018","journal-title":"J Intellect Disabil Res"},{"key":"10.1016\/j.rpsm.2023.01.003_bib0250","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S2215-0366(16)30191-2","article-title":"Reduction or discontinuation of antipsychotics for challenging behaviour in adults with intellectual disability: a systematic review","volume":"4","author":"Sheehan","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.rpsm.2023.01.003_bib0255","doi-asserted-by":"crossref","first-page":"e013116","DOI":"10.1136\/bmjopen-2016-013116","article-title":"Quality of prescribing of antipsychotic medication for people with intellectual disability under the care of UK mental health services: a cross-sectional audit of clinical practice","volume":"6","author":"Paton","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.rpsm.2023.01.003_bib0260","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1177\/070674371205701002","article-title":"Treatments for the challenging behaviours of adults with intellectual disabilities","volume":"57","author":"Matson","year":"2012","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.rpsm.2023.01.003_bib0265","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/jar.12089","article-title":"Assessment and treatment of challenging behaviour for individuals with intellectual disability: a research review","volume":"27","author":"Lloyd","year":"2014","journal-title":"J Appl Res Intellect Disabil"},{"key":"10.1016\/j.rpsm.2023.01.003_bib0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2788.2009.01232.x","article-title":"Pharmacotherapy for aggressive behaviours in persons with intellectual disabilities: treatment or mistreatment?","volume":"54","author":"Tsiouris","year":"2010","journal-title":"J Intellect Disabil Res"},{"key":"10.1016\/j.rpsm.2023.01.003_bib0275","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1136\/bmj.307.6897.184","article-title":"Neuroleptics, learning disability, and the community: some history and mystery","volume":"307","author":"Manchester","year":"1993","journal-title":"BMJ"},{"key":"10.1016\/j.rpsm.2023.01.003_bib0280","first-page":"CD000377","article-title":"Antipsychotic medication for challenging behaviour in people with learning disability","author":"Brylewski","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rpsm.2023.01.003_bib0285","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hup.748","article-title":"Reviewing the use of antipsychotic drugs in people with intellectual disability","volume":"21","author":"La Malfa","year":"2006","journal-title":"Hum Psychopharmacol"},{"issue":"Pt 10","key":"10.1016\/j.rpsm.2023.01.003_bib0290","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1365-2788.2007.00950.x","article-title":"The effectiveness of antipsychotic medication in the management of behaviour problems in adults with intellectual disabilities","volume":"51","author":"Deb","year":"2007","journal-title":"J Intellect Disabil Res"},{"key":"10.1016\/j.rpsm.2023.01.003_bib0295","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.rpsm.2023.01.003_bib0300","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.rpsm.2023.01.003_bib0305","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.rpsm.2023.01.003_bib0310","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12874-015-0034-x","article-title":"An accurate test for homogeneity of odds ratios based on Cochran's Q-statistic","volume":"15","author":"Kulinskaya","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.rpsm.2023.01.003_bib0315","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.rpsm.2023.01.003_bib0320","series-title":"Statistical Power Analysis for the Behavioral Sciences","first-page":"1","author":"Cohen","year":"1988"},{"key":"10.1016\/j.rpsm.2023.01.003_bib0325","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2788.2010.01352.x","article-title":"Olanzapine vs. risperidone in treating aggressive behaviours in adults with intellectual disability: a single blind study","volume":"55","author":"Amore","year":"2011","journal-title":"J Intellect Disabil Res"},{"key":"10.1016\/j.rpsm.2023.01.003_bib0330","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1177\/070674378002500604","article-title":"Comparison of SCH-12679 and thioridazine in aggressive mental retardates","volume":"25","author":"Elie","year":"1980","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.rpsm.2023.01.003_bib0335","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1192\/bjp.146.5.525","article-title":"Pipothiazine palmitate in the management of aggressive mentally handicapped patients","volume":"146","author":"Lynch","year":"1985","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.rpsm.2023.01.003_bib0340","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/jir.12584","article-title":"Is risperidone effective in reducing challenging behaviours in individuals with intellectual disabilities after 1 year or longer use? A placebo-controlled, randomised, double-blind discontinuation study","volume":"63","author":"Ramerman","year":"2019","journal-title":"J Intellect Disabil Res"},{"key":"10.1016\/j.rpsm.2023.01.003_bib0345","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0140-6736(08)60072-0","article-title":"Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial","volume":"371","author":"Tyrer","year":"2008","journal-title":"Lancet (Lond, Engl)"},{"key":"10.1016\/j.rpsm.2023.01.003_bib0350","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1600-0447.1975.tb00039.x","article-title":"Pipamperone (Dipiperon R3345) in troublesome mental retardates: a double-blind placebo controlled cross-over study with long-term follow-up","volume":"52","author":"van Hemert","year":"1975","journal-title":"Acta Psychiatr Scand"},{"issue":"Pt 5","key":"10.1016\/j.rpsm.2023.01.003_bib0355","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1046\/j.1365-2788.1999.043005360.x","article-title":"Antipsychotic medication for challenging behaviour in people with intellectual disability: a systematic review of randomized controlled trials","volume":"43","author":"Brylewski","year":"1999","journal-title":"J Intellect Disabil Res"},{"key":"10.1016\/j.rpsm.2023.01.003_bib0360","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.rasd.2014.03.021","article-title":"Psychopharmacological treatment of challenging behaviours in adults with autism and intellectual disabilities: a systematic review","volume":"8","author":"Sawyer","year":"2014","journal-title":"Res Autism Spectr Disord"}],"container-title":["Spanish Journal of Psychiatry and Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1888989123000046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1888989123000046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T18:19:36Z","timestamp":1759429176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1888989123000046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1888989123000046"],"URL":"https:\/\/doi.org\/10.1016\/j.rpsm.2023.01.003","relation":{},"ISSN":["2950-2853"],"issn-type":[{"value":"2950-2853","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological treatment for challenging behavior in adults with intellectual disability: Systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Spanish Journal of Psychiatry and Mental Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpsm.2023.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Espa\u00f1a, S.L.U. on behalf of SEP y SEPB.","name":"copyright","label":"Copyright"}]}}